# A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07439094/  
OnCo record `nct07439094` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CKD-703 in non-small-cell lung cancer, run by Chong Kun Dang Pharmaceutical, now recruiting.

## Summary

A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07439094 by Chong Kun Dang Pharmaceutical, with 140 participants planned, started 2026-04-16 and due to reach its primary completion in 2029-12. Interventions recorded: CKD-703.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07439094
- Phase: 1/2
- Setting: A First-in-Human, Multicenter, Open-Label, Phase 1/2a Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer
- Sponsor: Chong Kun Dang Pharmaceutical
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07439094: https://clinicaltrials.gov/study/NCT07439094

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07439094.json